TIANJIN TEDA BIOMEDICAL ENGINEERING COMPANY LIMITED Financials Tianjin TEDA Biomedical Engineering Company Limited
Equities
8189
CNE1000004H7
Agricultural Chemicals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.075 HKD | 0.00% |
|
-10.71% | -15.73% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 482.4 | 209.9 | 156.3 | 262.4 | 334.6 | 153.3 |
| Enterprise Value (EV) 1 | 481.4 | 223.1 | 175.4 | 325.3 | 423.4 | 230.9 |
| P/E ratio | -2.66 x | -2.48 x | -3.26 x | -6.21 x | -11.9 x | -7.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.37 x | 0.59 x | 0.42 x | 0.55 x | 0.74 x | 0.39 x |
| EV / Revenue | 1.37 x | 0.62 x | 0.47 x | 0.68 x | 0.94 x | 0.58 x |
| EV / EBITDA | -12 x | -7.45 x | -8.15 x | -22.8 x | -24.2 x | -20.7 x |
| EV / FCF | 11 x | 20.3 x | 3.29 x | -12.6 x | -50.8 x | -116 x |
| FCF Yield | 9.12% | 4.93% | 30.4% | -7.96% | -1.97% | -0.86% |
| Price to Book | 1.77 x | 1.1 x | 1.09 x | 2.6 x | 4.6 x | 3.07 x |
| Nbr of stocks (in thousands) | 1,894,500 | 1,894,500 | 1,894,500 | 1,894,500 | 1,894,500 | 1,894,500 |
| Reference price 2 | 0.2546 | 0.1108 | 0.0825 | 0.1385 | 0.1766 | 0.0809 |
| Announcement Date | 3/29/19 | 4/28/20 | 3/29/21 | 4/26/22 | 3/31/23 | 4/19/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 351.9 | 358.8 | 369.4 | 476.4 | 449.7 | 398 |
| EBITDA 1 | -40.11 | -29.94 | -21.52 | -14.27 | -17.52 | -11.14 |
| EBIT 1 | -63.88 | -38.63 | -25.57 | -18.39 | -27.12 | -19.34 |
| Operating Margin | -18.15% | -10.77% | -6.92% | -3.86% | -6.03% | -4.86% |
| Earnings before Tax (EBT) 1 | -300.5 | -88.82 | -50 | -44.84 | -26.5 | -12.01 |
| Net income 1 | -177.7 | -84.62 | -48 | -42.26 | -28.11 | -20.16 |
| Net margin | -50.49% | -23.59% | -13% | -8.87% | -6.25% | -5.07% |
| EPS 2 | -0.0958 | -0.0447 | -0.0253 | -0.0223 | -0.0148 | -0.0106 |
| Free Cash Flow 1 | 43.91 | 10.99 | 53.37 | -25.89 | -8.336 | -1.993 |
| FCF margin | 12.48% | 3.06% | 14.45% | -5.44% | -1.85% | -0.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/29/19 | 4/28/20 | 3/29/21 | 4/26/22 | 3/31/23 | 4/19/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 13.2 | 19.1 | 62.9 | 88.8 | 77.6 |
| Net Cash position 1 | 1.02 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.4399 x | -0.8884 x | -4.409 x | -5.068 x | -6.968 x |
| Free Cash Flow 1 | 43.9 | 11 | 53.4 | -25.9 | -8.34 | -1.99 |
| ROE (net income / shareholders' equity) | -69.4% | -35.7% | -27.9% | -33.7% | -27.5% | -15.1% |
| ROA (Net income/ Total Assets) | -6.9% | -5.96% | -4.23% | -3.1% | -4.95% | -3.77% |
| Assets 1 | 2,574 | 1,421 | 1,133 | 1,361 | 567.8 | 534.2 |
| Book Value Per Share 2 | 0.1400 | 0.1000 | 0.0800 | 0.0500 | 0.0400 | 0.0300 |
| Cash Flow per Share 2 | 0.0200 | 0.0100 | 0.0100 | 0.0100 | 0 | 0 |
| Capex 1 | 9.02 | 1.24 | 6.12 | 27.6 | 8.8 | 2.47 |
| Capex / Sales | 2.56% | 0.35% | 1.66% | 5.79% | 1.96% | 0.62% |
| Announcement Date | 3/29/19 | 4/28/20 | 3/29/21 | 4/26/22 | 3/31/23 | 4/19/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -15.73% | 18.15M | |
| +1.67% | 15.02B | |
| -14.18% | 14.5B | |
| +6.58% | 12.19B | |
| -13.63% | 9.72B | |
| -12.35% | 7.35B | |
| -.--% | 7.31B | |
| -3.81% | 4.18B | |
| -27.17% | 2.37B | |
| +2.63% | 2.06B |
- Stock Market
- Equities
- 8189 Stock
- Financials Tianjin TEDA Biomedical Engineering Company Limited
